Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous HSCT with BEAM + horse ATG for aggressive relapsing-remitting multiple sclerosis
ACTRN12616000151437Phase 2Recruiting
- Sponsor
- Austin Health
- Start
- Jan 2016
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide, carmustine, cytarabine, etoposide, melphalan and 4 more in multiple sclerosis (MS), sponsored by Austin Health. Primary endpoint: Safety. Started Jan 2016; status: recruiting.
02
Drugs
cyclophosphamidecarmustinecytarabineetoposidemelphalan
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on ACTRN12616000151437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12616000151437.